| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | 38.89% | Roth MKM | $9 → $7.5 | Maintains | Buy |
| 03/15/2021 | 196.3% | Roth Capital | $13.5 → $16 | Maintains | Buy |
| 11/18/2019 | 103.7% | Benchmark | → $11 | Initiates Coverage On | → Speculative Buy |
| 09/20/2019 | 71.3% | Roth Capital | → $9.25 | Initiates Coverage On | → Buy |
| 07/24/2019 | — | Janney Montgomery Scott | Downgrades | Buy → Neutral |
What is the target price for Champions Oncology (CSBR)?
The latest price target for Champions Oncology (NASDAQ: CSBR) was reported by Roth MKM on September 22, 2023. The analyst firm set a price target for $7.50 expecting CSBR to rise to within 12 months (a possible 38.89% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Champions Oncology (CSBR)?
The latest analyst rating for Champions Oncology (NASDAQ: CSBR) was provided by Roth MKM, and Champions Oncology maintained their buy rating.
When is the next analyst rating going to be posted or updated for Champions Oncology (CSBR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Champions Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Champions Oncology was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
Is the Analyst Rating Champions Oncology (CSBR) correct?
While ratings are subjective and will change, the latest Champions Oncology (CSBR) rating was a maintained with a price target of $9.00 to $7.50. The current price Champions Oncology (CSBR) is trading at is $5.40, which is out of the analyst's predicted range.
